Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in
the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition,
a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be
included; this subgroup will be analyzed in an exploratory manner only.